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Challenges and opportunities for oral
pre-exposure prophylaxis in the prevention of HIV
infection: where are we in Europe?
Jean-Michel Molina1,3*, Claire Pintado3, Caroline Gatey3, Diane Ponscarme3, Pierre Charbonneau3, Benedicte Loze3,
Willy Rozenbaum3 and Constance Delaugerre1,2
Abstract
Following US Food and Drugs Administration approval in July 2012 of daily oral tenofovir and emtricitabine for
pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals in the USA, there has been much
controversy about the implementation of this PrEP regimen in other countries throughout the world, and in Europe
in particular. In this review, we focus on the challenges and opportunities of a daily oral PrEP regimen to curb the
rising incidence of HIV infection in high-risk groups, and particularly in men who have sex with men. A number of
issues would need to be addressed before PrEP could be implemented, including assessing the real effectiveness
and cost-effectiveness of daily PrEP, the sustainability of daily adherence, the risk of selecting resistance, the
long-term safety, and the risk of change in sexual behavior that might offset the benefit of PrEP. Alternatives to a
daily oral PrEP regimen are being explored.
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Introduction
Pre-exposure prophylaxis (PrEP) is a new biomedical
intervention to prevent HIV acquisition in HIV-seronegative
high-risk individuals using anti-retroviral drugs before
HIV exposure.
In the wake of the recent US Food and Drug Admin-
istration (FDA) approval of a combined pill of
tenofovir disoproxil fumarate (TDF) and emtricitabine
(FTC) for daily PrEP to prevent sexual acquisition of
HIV in high-risk individuals, there has been much con-
troversy both in the medical and in men who have sex
with men (MSM) about implementation of PrEP [1]. In
a recent online survey of readers of the New England
Journal of Medicine, only 51% of 1,115 respondents
from 85 countries voted for the initiation of PrEP in a
46-year old man who has sex with men, multiple sexual
encounters, and who is asking whether he should re-
ceive PrEP [2]. Even in the USA, the uptake of PrEP
has been lower than expected, owing in part to limited
awareness, and a number of demonstration projects
are being implemented to assess real-life acceptability
and adherence to a daily PrEP regimen in high-risk indi-
viduals, mostly in men who have sex with men (MSM)
[3]. In Europe, PrEP is not yet approved, and research is
still ongoing to assess PrEP among MSM.
In this review, we focus on the various issues that would
need to be addressed before oral daily PrEP could be
implemented on a large scale and become a worldwide
public-health strategy for HIV prevention, particularly
among high-risk MSM and particularly in Europe.
Is there a need for PrEP in Europe?
Although the number of new HIV infections is slowly
decreasing in many European countries, there has been
no decline and even a small increase of new HIV infec-
tions in MSM. In France, for example, MSM account for
up to 40% of new HIV infections [4], and this is the only
risk group in which the prevalence of HIV infection has
increased over the past few years. Similar reports from the
UK show a similar rising number of new HIV infections in
MSM, despite an increasing number of these individuals
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being tested for HIV, and more HIV-infected patients
receiving antiretroviral therapy (ART), which results in
suppressed viral replication [5]. With an HIV incidence
in MSM that is 200-fold higher than that in the general
population and a concomitant increase in other sexually
transmitted infections (syphilis, gonorrhea, chlamydia,
and hepatitis C) there is a clear need for strengthening
prevention in this high-risk group [6]. Although use of the
currently available prevention tools (information and edu-
cation, regular use of condoms, change in sexual behavior,
regular testing for HIV, ART for the HIV-infected partner,
post-exposure prophylaxis with ART started immediately
after at-risk sexual intercourse) needs to be reinforced,
new tools such as PrEP might be an opportunity to foster
prevention in MSM in Europe, as no HIV vaccine is yet
available and male circumcision has not been shown to
prevent HIV transmission via the anal route.
Do we have enough confidence in PrEP effectiveness?
To date six large phase III efficacy trials of oral PrEP with
TDF or TDF/FTC have been conducted in high-risk indi-
viduals, but have yielded conflicting results [7-12] (Table 1).
Indeed, whereas all trials had a similar placebo-controlled
design and assessed the benefit of daily oral PrEP on
HIV incidence, efficacy outcomes ranged from a 75% re-
duction of HIV incidence among serodiscordant couples
in the Partners PrEP study, to a non-significant 49%
increase in HIV incidence in the TDF arm of the VOICE
(Vaginal and Oral Interventions to Control the Epidemic)
trial in high-risk young women. Only a single trial, iPrEx
(Chemoprophylaxis for HIV Prevention in Men who have
Sex with Men), has been carried out in MSM [7]. In this
trial, for which participants were mainly enrolled from low-
income and middle-income countries in South America,
the overall efficacy was a 44% reduction in HIV incidence,
but the lower bound of the 95% confidence interval of
treatment efficacy was only 15%, below the predefined
efficacy target of 30% [7]. Indeed, 30% is usually con-
sidered by regulatory authorities to be the lowest level
at which a preventive intervention would be associated
with a public-health benefit [13]. Such inconsistency
was not found in the three randomized trials assessing
the benefit of male circumcision for HIV prevention in
heterosexual men, where a similar 60% reduction of
HIV incidence was found with this one-time intervention,
which has now been implemented as a public-health strat-
egy in a number of countries with high endemic rates of
HIV to reduce incidence [14].
These discrepant results for PrEP effectiveness have
led European regulatory authorities to defer approval of
oral PrEP pending the results of ongoing PrEP trials being
conducted in Europe (PROUD, IPERGAY) and those of
open-label clinical trials (IPrEX Open Label Extension
(IPrEx-OLE) and Partners PrEP extension) and demon-
stration projects in the USA. Indeed, despite FDA ap-
proval, which was granted before the full results of the
VOICE trial were available, there is currently a low uptake
of PrEP in the USA. More evidence is therefore needed to
show the real effectiveness of oral PrEP, particular among
MSM, before implementation in Europe.
Why have there been conflicting results across PrEP trials?
The reasons for these discrepant results between PrEP
trials are not completely straightforward, and a number
of explanations have been proposed.
Like any medical intervention, PrEP works only when
it is taken, and we have learned from HIV-infected
patients how adherence to ART is crucial for achieving
optimal outcomes. The same is also true for PrEP, as its
efficacy in trials seemed to be strongly correlated to
adherence with this daily regimen (Table 1). Therefore,
differences in adherence rates between PrEP trials are
likely to be the main reason for these discrepant efficacy
results. Indeed, adherence, as measured by the propor-
tion of patients with drug levels detectable in plasma
ranged from 82% in the Partners PrEP study to as low as
30% in VOICE. We also learned from these trials that
adherence measured by self-report or pill count was not
reliable, and overestimated real adherence as measured
by plasma drug levels. In iPrEx, adherence measured by
plasma drug level was only 51%, but post hoc analyses
showed that only 7% of those infected in the active arm
Table 1 Efficacy and adherence rates across PrEP trials
Study [reference]: countries Population n Efficacy Lower bound of 95% CI Adherencea
Partners PrEP [8]: Kenya, Uganda Heterosexual couples 4758 67% TDF; 75% TDF/FTC 44% TDF; 55% TDF/FTC 82%
TDF2 Study [9]: Botswana Young men and women 1219 62% TDF/FTC 21.5% 80%
Bangkok TDF [12]: Thailand IVDU 2413 49% TDF 9.6% 67%
iPrEx [7]: S. America, SA, Thailand, USA MSM 2499 44% TDF/FTC 15% 51%
FEM-PrEP [10]: Kenya, SA, Tanzania Young women 2120 6% TDF/FTC −52% 37%
VOICE [11]: South Africa, Uganda, Zimbabwe Young women 5029 −49% TDF; - 4% TDF/FTC −130% TDF; −50% TDF/FTC 30%
Abbreviations: FTC, emtricitabine; IVDU, intravenous drug users; MSM, men who have sex with men; PrEP, pre-exposure prophylaxis; SA, South Africa; TDF,
tenofovir disoproxil fumarate.
aAdherence was assessed by the proportion of participants with drugs detectable in plasma and who remained free of infection in the active PrEP arms.
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had the drugs detectable in plasma at the time of infection,
which the authors translated into a 92% (95% CI 40–99)
efficacy of PrEP in those with drugs detected in plasma [7].
However, such a post hoc analysis is no longer protected by
randomization, and those individuals with high adherence
to PrEP might also be those most adherent to the other
preventive tools made available in the trial. Because it is
not possible to compare HIV incidence among patients
with high adherence to both PrEP and placebo (although
including a tracer in the placebo could be an option), such
an analysis should be taken with caution. Indeed, 31% of
participants in the active arms of the Partners PrEP trials
became infected while having detectable, sometimes high,
levels of drugs in their plasma, and such a correlation
between plasma drug levels and treatment efficacy did not
seem to be present in the VOICE trial [8,11].
Other explanations for these conflicting results have
also been proposed as there are major differences between
these trials in terms of gender, age, route of HIV acquisi-
tion, and rate of concomitant sexually transmitted infec-
tions among participants.
Young MSM (<25 years) in IPrEx had a two-fold higher
risk of HIV acquisition and also were more than three
time less likely to be adherent to PrEP [15]. In addition,
because the trials that failed (Fem-PrEP and VOICE) were
carried out in young women in sub-Saharan Africa, it is
therefore possible that this PrEP strategy may be less
effective in women. Although no significant difference in
terms of efficacy between men and women was reported
in the Partners PrEP trials, there was a non-significant
trend toward a lower efficacy of this strategy in women
than men with TDF/FTC (66% versus 84%) but not with
TDF alone (71% versus 63%) [8]. Nevertheless, should
it be confirmed that there is a difference in PrEP effi-
cacy between men and women, this could be explained
by the route of HIV acquisition and the differential
pharmacokinetics of these antiretroviral drugs in the
vaginal and rectal tissues. Indeed, pharmacokinetics studies
in healthy volunteers following oral dosing with TDF/FTC
have shown a 20-fold to 100-fold higher exposure to
TVF-DP (the phosphorylated active metabolite of TDF)
in rectal tissue compared with blood or vaginal and
cervical tissues [16].
Other factors associated with an increased risk of sexual
transmission of HIV might also be relevant to explain the
different outcomes of these various PrEP trials. In studies
performed in sub-Saharan Africa, younger age, high plasma
HIV viral load in the HIV-infected partner, lower use of
condoms, and incidence of sexually transmitted infections
(STIs), whether symptomatic or asymptomatic in the unin-
fected partners, were all independently associated with a
higher risk of HIV transmission [17,18]. It is therefore pos-
sible that HIV-seronegative participants in the Partners
PrEP trials, who were in a stable couple relationship for
several months were less exposed to HIV-infected partners
with primary HIV infection, which is a period of high risk
for HIV transmission because of very high viral loads in
plasma and genital secretions. In addition, the number of
sexual partners, and therefore the prevalence of STIs, is
likely to be much lower among stable couples than among
young men and women. The same statement could apply
to the use of condoms and sexual behavior in general,
which might explain why PrEP may work better in a setting
where the risk of HIV transmission per sexual act is lower.
Is oral PrEP safe enough?
There is a considerable weight of data available on the
safety of TDF/FTC as daily oral PrEP, and has so far
been reassuring, although the follow-up period in these
PrEP studies has been limited so far to a couple of years.
This safety profile is not unexpected, as TDF and FTC
have long been used for the treatment of HIV infection
and are considered the drugs of choice not only because
of their potent antiviral activity but also because of their
long-term safety. In terms of initial tolerability, participants
receiving PrEP have experienced more nausea and diarrhea
compared with those receiving placebo. Overall, there were
no more study treatment discontinuations in the active
arms than in the placebo arms of PrEP trials [7-12].
However, renal and bone toxicities are the two long-
term safety issues that need to be monitored in patients
taking TDF. Indeed, in previous PrEP trials, a few partic-
ipants had to discontinue treatment because of increased
creatinine levels, which usually returned to normal once
the drug was discontinued. In any case, only people with
normal creatinine clearance should receive TDF, and
both glomerular and tubular functions need to be
monitored regularly during TDF treatment. Similarly,
small reductions in bone-mineral density have been
reported in healthy participants of PrEP trials receiving a
TDF-containing PrEP regimen, but the clinical relevance
of this currently remains unknown [19].
The major threat of PrEP use is the risk for selecting
HIV drug-resistance-associated mutations. This selection
of resistance is of particular concern because both TDF
and FTC are the cornerstone of antiretroviral therapy
today, and their efficacy would be greatly jeopardized by
the emergence of such resistance mutations. Although
many options are available today for the treatment of pa-
tients with HIV infection, even in cases of drug-resistant
viruses, every effort should be made to avoid this risk of
selecting resistance. So far, in clinical trials, this risk of
selecting for HIV drug resistance among participants
who became infected despite PrEP has been low, in the
range of 7% of those assigned to receive PrEP [7-12]. In
fact, the large majority of participants who developed
resistance to TDF or FTC were those who were already
infected at the time they started PrEP, and it was expected
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that receiving a dual combination of anti-retrovirals could
lead to the emergence of resistance. That is the reason
why it is of utmost importance to exclude HIV infection
before starting any patient on PrEP, and we know that
current serological assays, especially rapid tests, can miss
primary HIV infection [20]. It is therefore essential to
defer PrEP prescription in a person who has symptoms
suggestive of primary HIV infection and to perform
PCR assays to detect HIV RNA in blood.
What is the cost-effectiveness of oral PrEP?
Few studies have addressed the crucial issue of cost-
effectiveness with the use of a daily oral PrEP regimen of
TDF and FTC. As a prerequisite for such cost-effectiveness
analyses, the strategy obviously needs to be effective in
trials. Here, we focus on cost-effectiveness studies in
MSM, based on the IPrEx results.
The first study looked at the cost-effectiveness of daily
PrEP for MSM in the USA using a dynamic model of
HIV transmission and progression with a detailed eco-
nomic analysis [21]. Benefits and costs of PrEP were then
assessed over 20 years of PrEP use by MSM. If 20% of all
MSM were to use PrEP, more than 62,000 new cases of
HIV infection would be prevented, with a resulting de-
clining prevalence of HIV by 10% at 20 years compared
with no PrEP [21]. However, the incremental cost for the
healthcare budget would be significant (USD 95 billion),
with a cost of more than USD 172,000 per quality-adjusted
life-year (QALY) much higher than would be considered to
be a cost-effective strategy. However, if PrEP were to be
used by 20% of those at high risk (defined as those with
more than 5 partners per year), 41,000 cases of HIV would
be prevented, with a similar reduction of HIV prevalence
by 10% at 20 years. This strategy would be a cost-effective
intervention, because it would cost approximately USD
40,000 per QALY gained; however, it would still be as-
sociated with an increase in healthcare expenditure of
about USD 14 billion over 20 years. It should be noted
that the authors warned that their sensitivity analysis
indicated that if there were to be a decrease of 20% in
condom use, a paradoxical increase of 4% in new HIV
infections could occur.
Another assessed the cost-effectiveness of this strategy
in Peru, where most recruitment in the IPrEx study took
place. In that study, the daily PrEP strategy with TDF/
FTC would not be cost-effective using the World Bank
threshold at the current cost of TDF/FTC [22]. Only
certain optimistic scenarios combining a low coverage of
only 5% of MSM with high prioritization to those at
higher risk could be cost-effective.
These data help to explain the current reluctance of
health authorities in a number of countries to imple-
ment PrEP, and this also applies to Europe. Further-
more, the issue of reimbursement is a sensitive one, as
the principles of access equity should apply to newly
approved drugs.
What is the risk associated with risk compensation during
PrEP use?
Risk compensation, which in this case can be defined as
a sexual behavior with higher risk for HIV acquisition
(for example, reduced condom use or condomless sex,
increasing number of sexual partners), is a possible factor
that could jeopardize current efforts in the field of HIV
prevention. Theoretically, people using PrEP might feel
protected against HIV and therefore be less prone to use
condoms, or be willing to extend the number of their sex-
ual partners. Online surveys among MSM indicate that
this could be indeed the case. In a French study, up to
27% of respondents reported that they might stop condom
use and 42% that they might reduce condom use if PrEP
were to become available [23]. In addition, some respon-
dents feared that the availability of PrEP might encourage
their sexual partners to ask for condomless sex. Hence,
there is a general concern that PrEP availability might de-
crease condom use, which could therefore offset the po-
tential benefit of this therapy in preventing HIV infection,
and ultimately this could even lead to an increase in the
number of new HIV infections.
However, it should be noted that none of the PrEP trials
to date found evidence of sexual disinhibition, and this
finding was reasonably consistent across trials [7-11]. In
fact, there was, on the contrary, a small but significant
decrease in the number of receptive anal intercourse and
a small but significant increase in condom use during the
course of the IPrEx trial compared with baseline [7].
This reduction in high-risk sexual behavior in all PrEP
trials is likely to be a consequence of the close counsel-
ing that participants involved in those trials received. It
would therefore be essential to provide this same kind of
support outside trials to avoid the risk of disinhibition. It
should also be remembered that in all the placebo-
controlled PrEP trials to date, the participants did not
know whether they were receiving an active drug or a
placebo, and therefore might have been more receptive
to counseling. Whether this would hold true in real-life
settings needs further study and the open-label exten-
sion phases of the IPrEx and Partners PrEP trials should
be informative in that respect.
Is the high level of adherence required with daily PrEP
sustainable?
If we assume that the efficacy of PrEP is associated with
high adherence rates, then based on previous studies,
treatment should aim at an adherence rate of at least
80%, as observed in Partners PrEP [8].
It is interesting to analyze the reasons why adherence was
so high in that trial compared with others performed in
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similar settings in sub-Saharan Africa. After conducting in-
depth qualitative interviews, Ware et al. elegantly identified
a number of factors that might explain the differences in
adherence rates between a seronegative partner in an HIV-
serodiscordant couple, and an unmarried man or woman
[24]. Within a serodiscordant couple, there is a ‘discordant
dilemma’ for the seronegative partner: trying to avoid HIV-
infection while preserving the relationship in a context of
desire for children and inconvenient long-term use of con-
doms. In these couples, PrEP can be seen as a solution,
safeguarding health without ending the relationship. PrEP
users are also likely to benefit from the support of their
HIV-infected partners to improve their adherence. This is
in sharp contrast with studies of young MSM, whose adher-
ence to daily PrEP waned over a period of only 6 months
from 63% to only 20% [25].
There is also demographic and geographic variability
in adherence across PrEP trials, with older participants
and those enrolled in sites in the USA showing usually
higher adherence rates compared with younger partici-
pants or those enrolled in non-USA sites [7]. Eventually, it
will be essential to assess PrEP adherence in open-labeled
extensions of placebo-controlled trials or of demonstra-
tion projects. Indeed, adherence might be higher among
people willing to take oral PrEP who are aware of the
benefit shown in PrEP trials if participants had high rates
of adherence to a daily regimen. In this regard, recent data
from participants of the open label extension of the iPrEx
study (IPrEx-OLE), showing an increase in adherence rate
(measured by drug detection in plasma) from 61% during
the placebo-controlled phase of the trial to 71% in the
open-label extension, is reassuring [26].
Therefore ways to improve adherence to PrEP are
needed if this strategy is to be successful. Providing
long-term support for adherence will be crucial even if
adherence might be higher in real life than it was in trials
as a result of the known efficacy of PrEP. Monitoring
adherence during PrEP will also be key, although data on
adherence assessed by self-report or pill count are not fully
reliable. Real-time monitoring of plasma drug levels could
be an option, and new and more reliable assays based on
measurements of tenofovir-diphosphate (TFV-DP) or FTC-
triphosphate (FTC-TP) in peripheral blood mononuclear
cells (PBMCs) or red cells using dry blood spots are being
developed, which are likely be useful in developing coun-
tries in particular [27]. Assays have also been devised to
measure drug exposure in hair [28].
Alternatives to daily oral PrEP
Following the first encouraging results of PrEP trials,
and FDA approval of TDF/FTC for PrEP, research in this
area has been exploding. New oral drugs are being
tested, as well as new drug combinations. Maraviroc, an
HIV entry inhibitor already approved for the treatment
of HIV infection, has entered clinical trials. Maraviroc can
be dosed once daily, has a good safety profile, and achieves
high levels in vaginal secretions and rectal tissue. Its safety
and pharmacokinetics is currently being assessed in the
HPTN 069 trial (Next-PrEP), both alone and in combin-
ation with TDF or FTC, in high-risk MSM and women.
As more acceptable PrEP regimens are being developed
to improve adherence, there has been great interest in
intermittent PrEP. Indeed, in animal models, oral intermit-
tent PrEP, given at the time of virus inoculation, whether by
vaginal or rectal challenge, provided an efficacy similar to
that provided by use of daily PrEP [29]. This strategy of
coitus-dependent PrEP is currently being assessed in two
PrEP trials in MSM, under the assumption that the con-
venience of the regimen could increase PrEP adherence
and therefore PrEP efficacy [30,31]. Interestingly, in young
heterosexual women, coitus-dependent use of TDF gel was
able to significantly reduce the incidence of HIV infection,
whereas daily use of TDF gel in a similar population failed
to show a significant benefit, suggesting that the conveni-
ence of the regimen plays an important role in PrEP adher-
ence [11,32]. Should it prove to be effective, intermittent
PrEP is likely to be attractive to users, and is also likely to
be more cost-effective and less toxic than a daily regimen.
In addition, sexual activity is often pre-planned for and con-
centrated during weekends, and is then usually not per-
manent, thus if this intermittent PrEP strategy is proven
effective, high-risk individuals might be likely to adapt their
behavior to it. Indeed, in a recent online French survey of
MSM, 62.8% of 939 seronegative MSM favored ‘on-de-
mand’ PrEP compared with only 24.6% who favored daily
PrEP [23]. Interest for ‘on-demand’ PrEP was also reported
in another study [33]. This strategy of event-based dosing
seems best suitable for MSM who more frequently use sex-
ual networking websites, with only 15% of them having anal
sex more than 3 days a week [34]. This intermittent strategy
might also be particularly attractive in young MSM because
a fairly high proportion (58%) reported being intermittently
adherent to PrEP [35].
Intermittent PrEP could also be designed as a fixed
weekly regimen. This would have the advantage of not
being related to sexual activity, and therefore would be
potentially less prone to missed doses in cases when sexual
activity could not be anticipated. Indeed, TDF and FTC
both have long intracellular half-lives, suggesting that less
than daily dosing could be sufficient to provide similar pro-
tection to a daily regimen. Interestingly, when comparing
TFV-DP concentrations in the PBMCs of participants in
the active arm of IPrEx who remained uninfected with
those obtained in healthy volunteers receiving different
TDF/FTC dosing regimens, Anderson et al. suggested that
TDF/FTC regimens with at least four tablets/week would
achieve TFV-DP concentrations in PBMCs, associated with
a 90% reduction in the risk of HIV acquisition in IPrEx
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[36]. Even those receiving only two tablets/week could get
some degree of protection against HIV infection. Trials are
under way to assess the pharmacokinetics and adherence
rate to these fixed-dose intermittent regimens [31].
Other modes of PrEP delivery could also be attractive
for intermittent use. In particular, parenteral injections
of long-acting antiretroviral agents could be a way to over-
come the issue of PrEP adherence [37]. Preliminary studies
in monkeys have shown the benefit of this strategy using
monthly intramuscular injections [38]. Finally, other modes
of PrEP delivery for men (rectal gels with TDF) and women
(antiretroviral-containing gels, films, or rings) are being
assessed, but are beyond the scope of this review.
However, the efficacy assessment of these new PrEP
regimens will raise funding, logistical, and ethical issues.
Prevention studies are complex studies to perform, need
strong community engagement to enroll large numbers
of participants, and should offer to all participants the
best standard of prevention.
Conclusions
Oral PrEP with anti-retroviral drugs is a new biomedical
tool that could help reduce the risk of HIV infection in
high-risk individuals. Because of the challenges and limita-
tions of the current daily PrEP regimens with TDF/FTC
combinations, this strategy has not yet been implemented
as a public-health strategy to reduce the continuing high
number of new HIV infections. More research and new
PrEP strategies have to be assessed [39]. In this regard, the
outcome of current ongoing trials in Europe and the USA
with oral PrEP, demonstration projects in the USA,
and open-label extension of already completed placebo-
controlled trials will be essential. In addition, PrEP should
not be seen as an alternative to current HIV preventive
strategies but rather as a complementary tool that people
might want to use to further reduce their risk of HIV
acquisition. PrEP should therefore be delivered within ap-
propriate settings, where other prevention measures could
also be reinforced and regular testing for HIV infection
and monitoring of PrEP safety is available.
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